| Cat. No. |
Product Name |
Information |
| PC-26449 |
VU041
Mosquito Kir1 inhibitor
|
VU041 is a selective inhibitor of mosquito Anopheles (An.) gambiae and Aedes (Ae.) aegypti inward rectifier potassium (Kir) channels with IC50 of 496 nM for AnKir1. |
| PC-26326 |
AN11736
Antiparasitic
|
AN11736 is a potent small molecule inhibitor of Trypanosoma congolense (T. congolense) and Trypanosoma vivax (T. vivax) parasites with IC50 of 0.15 nM and 1.3 nM respectively. |
| PC-26325 |
Enfiborole
Antiparasitic
|
Enfiborole is a potent small molecule inhibitor of Trypanosoma congolense (T. congolense) and Trypanosoma vivax (T. vivax) parasites with IC50 of 0.14 nM and 0.07 nM respectively. |
| PC-26055 |
MMV1581361
PfATP4 inhibitor
|
MMV1581361 is a potent inhibitor of Plasmodium falciparum ATP4 (PfATP4), inhibits 3D7 P. falciparum Strain with IC50 of 0.03 uM, disrupts Na+ ion homeostasis in P. falciparum. |
| PC-25995 |
SB5-171
PfCLK3 inhibitor
|
SB5-171 is a potent, covalent PfCLK3 inhibitor with IC50 of 10 nM, shows potent antiparasitic activity (EC50=104 nM). |
| PC-25444 |
Schistosome p97 inhibitor 739
Parasite p97 inhibitor
|
Schistosome p97 inhibitor 739 is a potent, selective and covalent inhibitor of parasite p97 with IC50 of 150 nM and 320 nM for S. mansoni and H. sapiens p97 respectively. |
| PC-25438 |
Clocinizine
Antiparasite
|
Clocinizine is a chlorinated analogue of cinnarizine, shows potent antischistosomal activity against both male and female parasites with EC50 and EC90 of 4.6 uM and 5.9 uM respectively. |
| PC-25297 |
Fexinidazole
T. brucei inhibitor
|
Fexinidazole (HOE 239) is an orally active, potent nitroimidazole antitrypanosomal agent, shows trypanocidal activity against T. brucei subspecies and strains with IC50 of 0.7-3.3 uM, has the potential for human sleeping sickness (HAT) caused by infection with T. brucei. |
| PC-25292 |
DNDI-VL-2098
Visceral leishmaniasis inhibitor
|
DNDI-VL-2098 is an orally effective preclinical drug candidate for visceral leishmaniasis (VL) with IC50 of 0.17 uM for L. infantum. |
| PC-25291 |
DNDI-0690
Visceral leishmaniasis inhibitor
|
DNDI-0690 is a clinical drug candidate for visceral leishmaniasis (VL), demonstrated excellent in vitro activity against three Old World and three New World cutaneous Leishmania strains (EC50<5 uM). |
| PC-25290 |
DNDI-5561
T. cruzi inhibitor
|
DNDI-5561 is a small molecule inhibitor of T. cruzi and L. infantum with IC50 of 38 uM and 0.2 uM. |
| PC-25202 |
BKI-1841
CpCDPK1 inhibitor
|
BKI-1841 is a highly potent, specific Cryptosporidium calcium-dependent protein kinase 1 (CDPK1) inhibitor with IC50 of 3 nM (CpCDPK1, C. parvum CDPK1) and EC50 of 0.7 uM against C. parvum parasites in Nanoluciferase assays. |
